Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1119 Results

Title
Intervention Indication Therapeutic Area Year Actions
Bupivacaine and meloxicam (HTX-011) for post-operative pain HTX-011 (Zynrelef) (fixed dose combination: Bupivacaine; Meloxicam) Post-operative pain Pain Relief 2019 View  |  Download
Bulevirtide for chronic hepatitis delta virus infection Bulevirtide (Myrcludex B) Chronic hepatitis D Hepatology , Infectious Disease 2020 View  |  Download
Budesonide suspension for treating eosinophilic oesophagitis in children and adolescents Budesonide orodispersible (Jorveza) Eosinophilic oesophagitis Gastroenterology , Immunology 2023 View  |  Download
Budesonide granules for induction of remission in lymphocytic colitis – first line Budesonide gastro-resistant (Budenofalk) Lymphocytic colitis Gastroenterology , Immunology 2020 View  |  Download
Budesonide for Ulcerative Proctitis Budesonide gastro-resistant (Budenofalk) Ulcerative proctitis Gastroenterology 2021 View  |  Download
Brolucizumab for visual impairment due to diabetic macular oedema Brolucizumab (RTH258; ESBA1008; Beovu) Visual impairment Endocrine Nutritional and Metabolic Disorders , Ophthalmology 2020 View  |  Download
Brolucizumab (ESBA1008; RTH258) for neovascular age-related macular degeneration (nAMD) Brolucizumab (RTH258; ESBA1008; Beovu) Age-related macular degeneration (AMD) Ophthalmology 2017 View  |  Download
Brigatinib for locally advanced or metastatic, ALK-positive, non-small cell lung cancer – first line Brigatinib (Alunbrig; AP26113) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Brigatinib for ALK-positive, locally advanced or metastatic, non-small cell lung cancer previously treated with alectinib or ceritinib Brigatinib (Alunbrig; AP26113) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer Brigatinib (Alunbrig; AP26113) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2017 View  |  Download
1 2 93 94 95 96 97 111 112
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications